Argent BioPharma Acquires AusCann Group's Key Assets

Aug 28, 2025
Argent BioPharma Ltd. has signed a binding term sheet to acquire the core assets and intellectual property of AusCann Group Holdings Ltd., enhancing its clinical pipeline and European presence.

Argent BioPharma Ltd. has signed a binding term sheet to acquire the core assets and intellectual property of AusCann Group Holdings Ltd., announced in a press release. This acquisition includes the Neuvis® drug delivery platform, FDA-facing epilepsy pre-clinical data, and EU-GMP manufacturing capabilities.

The USD 15 million share-based transaction is set to strengthen Argent's lead programs, CannEpil® and CimetrA®, while expanding its European footprint. The acquisition also adds significant audited assets, enhancing Argent's net stockholders' equity and supporting its planned dual U.S. national exchange listing.

As part of the acquisition, Mr. Andrew Chapman will join Argent's Board as Executive Director, bringing expertise in capital markets and biotech. The transaction is expected to complete in Q3 2025, subject to customary closing conditions, with integration planning already underway.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)
Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.